Storys aus Dubai

Filtern
  • 10.08.2022 – 17:51

    News Direct

    CleverTap Raises US$105M in Series D Funding Round Led by CDPQ

    Mountain View (California), Mumbai (India) and Montreal (Canada) (ots) - --News Direct-- CleverTap, a leading global B2B SaaS platform for customer engagement and retention today announced it has signed definitive agreements to raise US$105M in a Series D funding round led by CDPQ, a global investment group who committed US$75M, with participation from IIFL AMC’s Tech Fund, along with existing investors Tiger Global and ...

  • 05.08.2022 – 07:00

    Firmenich

    FIRMENICH DELIVERS RECORD RESULTS DESPITE CHALLENGING MACRO-ECONOMIC ENVIRONMENT

    Geneva (ots/PRNewswire) - Achieves double-digit Revenue and Adjusted EBITDA growth, coupled with strong cash generation, while prioritizing customer service Firmenich International SA, the world's largest privately-owned Fragrance and Taste company, announces its Full Year Results for the 52 weeks ended 30 June 2022. Financial Highlights - Revenue of CHF 4,723 million, ...

  • 20.05.2022 – 16:58

    LunaJets

    LunaJets Nearly Doubles Revenue but Sees Clouds Ahead

    Geneva (ots/PRNewswire) - The European Market Leader Sees Unsustainable Revenue Growth. EBACE 2022 As the private aviation charter market continues to enjoy a "new golden age", Geneva based LunaJets warns at this EBACE of a hard landing as it sees more signs of market bubbles. "This year-to-date, our growth is over 90%, considering a $110M revenue in 2021 for our private jet charter division" comments Guillaume Launay, ...

  • 29.04.2022 – 19:43

    Hikma Pharmaceuticals PLC

    Hikma confirms that it has not signed a licensing agreement with Opiant Pharmaceuticals

    London (ots/PRNewswire) - Hikma Pharmaceuticals PLC (Hikma) confirms that it has not entered into any transaction with Opiant Pharmaceuticals, contrary to a PR Newswire announcement issued today indicating that Opiant Pharmaceuticals and Hikma have entered into a commercialisation and license agreement for OPNT003, Nasal Nalmefene, in Europe and the UK. About Hikma ...

  • 30.03.2022 – 11:00

    Builder.ai

    Builder.ai Raises $100M Series C Funding Led by Global Software Investor Insight Partners

    London (ots/PRNewswire) - New funding takes Builder.ai's total raise to $195M, accelerating growth and enhancements of its human-assisted AI app development platform that empowers every business and entrepreneur Builder.ai® today announced an investment of $100 million in a Series C funding round led by Insight Partners, a New York-based global venture capital and ...